Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OTI-010

Cell therapy (Stem-cell derived) · developed by Mesoblast International Sàrl

Phase 2 Most advanced trial (none active)
MESO Developer
1 Registered trials

What is OTI-010?

OTI-010 is an autologous expanded mesenchymal stem cell product, made from multipotent stromal cells harvested from the patient's bone marrow and grown in vitro. When injected back into the patient, the cells may differentiate into mesenchyme-derived cell types and may augment bone marrow engraftment after whole-body irradiation. It is studied in graft versus host disease, leukemia and myelodysplastic syndromes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Therapy area
Oncology
Developer
Mesoblast International Sàrl (MESO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00081055 Phase 2 Graft Versus Host Disease Withdrawn MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes

More from Mesoblast International Sàrl

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind OTI-010

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.